A Phase 1 trial of intravenous boronophenylalanine-fructose complex in patients with glioblastoma multiforme

Conference · Tue Oct 01 00:00:00 EDT 1996

OSTI ID:390617

Bergland, R; Elowitz, E; Chadha, M ^[1]; Coderre, J A; Joel, D ^[2]

---

1. Beth Israel Medical Center, New York, NY (United States)
2. Brookhaven National Lab., Upton, NY (United States)

Boron neutron capture therapy (BNCT) of glioblastoma multiforme was initially performed at the Brookhaven National Laboratory in the early 1950`s While this treatment for malignant brain tumors has continued in Japan, new worldwide interest has been stimulated by the development of new and more selective boron compounds. Boronophenylalanine (BPA) is a blood-brain barrier penetrating compound that has been used in BNCT of malignant melanomas. SPA has been employed experimentally in BNCT of rat gliosarcoma and has potential use in the treatment of human glioblastoma. As a preface to clinical BNCT trials, we studied the biodistribution of SPA in patients with glioblastoma.

• Research Organization: Brookhaven National Lab. (BNL), Upton, NY (United States)
• Sponsoring Organization: USDOE, Washington, DC (United States)
• DOE Contract Number: AC02-76CH00016
• OSTI ID: 390617
• Report Number(s): BNL-63412; CONF-9410281-7; ON: DE97000007; TRN: 96:029178
• Resource Relation: Conference: 6. international symposium on neutron capture therapy for cancer, Kobe (Japan), 31 Oct - 4 Nov 1994; Other Information: PBD: 1996
• Country of Publication: United States
• Language: English

Related Subjects

55 BIOLOGY AND MEDICINE
BASIC STUDIES
BORON COMPOUNDS
THERAPEUTIC USES
NEOPLASMS
NEUTRON CAPTURE THERAPY
BRAIN
BLOOD-BRAIN BARRIER